Advertisement

Topics

FDA grants nivolumab accelerated approval for some relapsed paediatric colorectal cancers

06:32 EDT 2 Aug 2017 | ecancermedicalscience

On July 31, 2017, the U.S. Food and Drug Administration granted accelerated approval to nivolumab for the treatment of patients 12 years and older with mismatch repair deficient (dMMR) and microsatellite instability high (MSI-H) metastatic colorectal...

Original Article: FDA grants nivolumab accelerated approval for some relapsed paediatric colorectal cancers

NEXT ARTICLE

More From BioPortfolio on "FDA grants nivolumab accelerated approval for some relapsed paediatric colorectal cancers"

Quick Search
Advertisement